Literature DB >> 10587774

Pharmacological treatment of depression. Consulting with Dr Oscar.

M J Berber1.   

Abstract

OBJECTIVE: To review the pharmacological treatment of depression and to evaluate current strategies for treatment to maximize the benefits of antidepressant medications. QUALITY OF EVIDENCE: MEDLINE was searched to January 1999, using the headings depression, combination, augmentation, lithium, triiodothyronine, pindolol, buspirone, methylphenidate, and electroconvulsive therapy, for randomized controlled trials, systematic overviews, and consensus reports. Recent high-quality reviews were often found. References from papers retrieved were scrutinized for other relevant reports. Preference was given to more recent articles and well-designed studies. Recommendations from academic groups were analyzed. MAIN MESSAGE: Optimization of antidepressant therapy is the cornerstone of pharmacological treatment of depression. When symptoms persist despite optimization, further strategies include substitution, combination, augmentation, and reviewing and sometimes referring. Decisions are based on the evidence supporting the various strategies.
CONCLUSIONS: Antidepressants will work only if prescribed correctly. Awareness of the strategies for using antidepressants and evaluating their effectiveness improves primary care physicians' ability to treat this common disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10587774      PMCID: PMC2328680     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  12 in total

1.  Cognitive-behavioral management of drug-resistant major depressive disorder.

Authors:  G A Fava; G Savron; S Grandi; C Rafanelli
Journal:  J Clin Psychiatry       Date:  1997-06       Impact factor: 4.384

2.  Adequacy and duration of antidepressant treatment in primary care.

Authors:  W Katon; M von Korff; E Lin; T Bush; J Ormel
Journal:  Med Care       Date:  1992-01       Impact factor: 2.983

Review 3.  Dose-response relationship with venlafaxine.

Authors:  J E Kelsey
Journal:  J Clin Psychopharmacol       Date:  1996-06       Impact factor: 3.153

4.  Triiodothyronine potentiation of fluoxetine in depressed patients.

Authors:  R T Joffe
Journal:  Can J Psychiatry       Date:  1992-02       Impact factor: 4.356

Review 5.  Electroconvulsive therapy in the treatment-resistant patient.

Authors:  D P Devanand; H A Sackeim; J Prudic
Journal:  Psychiatr Clin North Am       Date:  1991-12

6.  A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group.

Authors:  G E Clerc; P Ruimy; J Verdeau-Pallès
Journal:  Int Clin Psychopharmacol       Date:  1994-09       Impact factor: 1.659

Review 7.  Pindolol augmentation of antidepressant therapy.

Authors:  R McAskill; S Mir; D Taylor
Journal:  Br J Psychiatry       Date:  1998-09       Impact factor: 9.319

8.  Medication resistance and clinical response to electroconvulsive therapy.

Authors:  J Prudic; H A Sackeim; D P Devanand
Journal:  Psychiatry Res       Date:  1990-03       Impact factor: 3.222

9.  Differential relapse following cognitive therapy and pharmacotherapy for depression.

Authors:  M D Evans; S D Hollon; R J DeRubeis; J M Piasecki; W M Grove; M J Garvey; V B Tuason
Journal:  Arch Gen Psychiatry       Date:  1992-10

Review 10.  Lithium augmentation of antidepressants in treatment-refractory depression.

Authors:  S Heit; C B Nemeroff
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

View more
  1 in total

1.  Access to adequate outpatient depression care for mothers in the USA: a nationally representative population-based study.

Authors:  Whitney P Witt; Abiola Keller; Carissa Gottlieb; Kristin Litzelman; John Hampton; Jonathan Maguire; Erika W Hagen
Journal:  J Behav Health Serv Res       Date:  2009-10-17       Impact factor: 1.505

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.